Granules India Acquires Senn Chemicals to Expand Peptide Focus

Granules India Limited today announced the successful closing of the acquisition of Senn Chemicals AG, a Swiss- based Contract Development and Manufacturing Organization (CDMO) specializing in peptide development and manufacturing. This marks a strategic milestone in Granules’ transformation into a science- and innovation-led organization and extends its capabilities into the fast- growing peptide therapeutics segment.

The acquisition follows the signing of a definitive share purchase agreement in February 2025, under which Granules, through its wholly owned Indian subsidiary, Granules Peptides Private Limited, acquired 100% of the equity of Senn Chemicals from the founding Senn family. Founded over 60 years ago, Senn Chemicals has built a strong reputation as a specialist in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), serving innovators and brand owners across pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets.

The Senn Chemicals brand and its operations in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus.

Dr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India, said, "The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science- and innovation-led organization. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialized CDMO capabilities, we are well- positioned to deliver high-quality, next-generation treatments. Senn’s specialized expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach. Together, we aim to drive meaningful impact in the complex therapeutics space."

The acquisition will enable Granules to accelerate development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in anti- diabetic, anti-obesity, and other next-generation therapeutic areas. Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned.

This transaction also marks Granules’ foray into the CDMO space, with Senn’s established CDMO business providing a strong platform for growth. The acquisition enhances Granules’ global footprint and provides access to a regulated market client base and highly skilled scientific talent in Europe.